While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.
Last trade$17.93
Day change-$0.725 (-3.89%)
Day range$17.76 – $18.73
Volume2,616,163
Market cap$5.25B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.25B
Price / earnings
—
Price / book
1.45×
Price / sales
1.64×
EV / sales
1.58×
EV / EBITDA
-47.55×
Profitability
Earnings per share
-$1.15
Return on assets
-6.87%
Return on equity
-8.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.81×
Quick ratio
1.36×
Cash ratio
0.26×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
—
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MMED, quarterly periods
Line item
Q1 FY2027 Jul 31, 2026
Q4 FY2026 Apr 30, 2026
Revenue
$843M
$837M
Cost of revenue
$378M
$357M
Gross profit
$465M
$480M
Selling, general and administrative
$312M
$299M
Research and development
$115M
$99M
Total operating expenses
$461M
$573M
Operating income
$4M
-$93M
Interest expense
$0
$0
Income before taxes
$4M
-$92M
Income taxes
$4M
$93M
Net income
$0
-$185M
Net income attributable to common shareholders
$0
-$185M
EBITDA
$43M
-$86M
Basic earnings per share
$0.00
—
Diluted earnings per share
$0.00
—
Recent news
Company coverage with links to the original publishers.
Medtronic completed a spinoff of its diabetes segment (MiniMed) and retired 55 million shares without cash expenditure, which will boost future EPS. The company reported strong Q1 FY2027 results with 14% revenue growth and is approaching Dividend King status (49 consecutive years of increases). Despite operational improvements and a reinvigorated pipeline with 50+ FDA approvals, Medtronic trades at a discount to medtech peers.
Medtronic and MiniMed Group posted better-than-expected first-quarter revenues, driving their shares up 1.5% and 10.7% respectively. However, NIO Inc. fell 4% after missing revenue estimates. Apple gained 2.6% following the appointment of John Ternus as new CEO.
The article recommends three dividend-paying stocks for long-term investors: United Parcel Service (UPS), Hormel Foods (HRL), and Medtronic (MDT). Despite being deeply unloved and trading significantly below their 2022 highs, all three companies are undergoing business transformations with early signs of success. Each offers attractive dividend yields (6.5%, 5.6%, and 3.6% respectively) and operates in essential industries, making them suitable for holding through market uncertainty.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.